Skip to main content

Primary Sclerosing Cholangitis clinical trials at UC Davis

3 research studies open to eligible people

Showing trials for
  • A Study of Experimental PLN-74809 in Cholangitis and Suspected Liver Fibrosis

    open to eligible people ages 18-75

    A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis

    Sacramento, California and other locations

  • A Study of Experimental Sulfasalazine for Primary Sclerosing Cholangitis (inflammation and scarring of the bile ducts)

    “This research study hopes to find out if experimental treatment with sulfasalazine can help people with PSC.”

    open to eligible people ages 15-80

    This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC.

    Davis, California and other locations

  • A Study of Volixibat to Treat Itching Caused by Primary Sclerosing Cholangitis

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 18 years and up

    The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

    Sacramento, California and other locations